1. Introduction {#sec1}
===============

Cannabis has been used for centuries, both recreationally and for medicinal purposes ([@bib30]). In the brain, endogenous cannabinoids are released postsynaptically and act in a retrograde manner on presynaptic cannabinoid receptors, suppressing further release of neurotransmitters ([@bib46], [@bib69]). There are two types of presynaptically-located cannabinoid receptors, CB~1~ and CB~2~. CB~1~ receptors are predominantly found in the central nervous system, whereas CB~2~ receptors are mainly located on immune cells (see [@bib47] for a review), although there are also CB~2~ receptors located in the rat cochlear nucleus that could have a functional role ([@bib2]). In the auditory system, CB~1~ receptors are present in the spiral ganglion ([@bib55]), dorsal and ventral cochlear nucleus ([@bib36], [@bib75], [@bib73]), medial nucleus of the trapezoid body ([@bib32]), the inferior colliculus ([@bib41]) and the auditory cortex ([@bib15]). Their presence throughout the auditory system suggests that they play a major role in synaptic regulation ([@bib20], [@bib40]). However, there are relatively few studies examining how activation of cannabinoid receptors affect the function of the auditory system. We sought to examine whether a highly-selective CB~1~ agonist could be a potential candidate target for attenuating auditory effects caused by sodium salicylate.

Sodium salicylate, the primary metabolite of aspirin in the body ([@bib50]), is commonly used experimentally in animals, as it is known to cause a variety of auditory effects, including tinnitus, hyperacusis and temporary hearing loss ([@bib42], [@bib39], [@bib12], [@bib8], [@bib71]). Ototoxic effects of salicylate are evident in (1) reduced distortion product otoacoustic emissions (DPOAEs) ([@bib68], [@bib57]), indicative of reduced outer hair cell activity; 2) a reduction in wave I auditory brainstem responses (ABRs; [@bib3]), indicative of reduced spiral ganglion activity; and 3) reduced amplitude of cochlear compound action potentials ([@bib44], [@bib57]), indicative of reduced cochlear sensitivity, particularly at high frequencies. Contrastingly, cortical evoked responses are enhanced following salicylate administration ([@bib70], [@bib62], [@bib45], [@bib3]), suggestive of a neural correlate of hyperacusis. Furthermore, reductions in alpha band activity are evident in the auditory cortex of animals following salicylate administration ([@bib60], [@bib3]), which have been suggested as a correlate of reduced inhibition related to the presence of tinnitus in humans ([@bib67], [@bib35]).

While there may be differences in the mechanisms underlying the effects of salicylate and noise exposure, which is the primary cause of these conditions in humans, salicylate is particularly useful as it reliably induces tinnitus, hyperacusis and hearing loss in animals when administered at a high dose (e.g. [@bib26], [@bib34], [@bib4], [@bib3]), as opposed to the variability observed following noise exposure. Furthermore, these effects are rapid, evident within 2 h in an animal model ([@bib57], [@bib3]). It is therefore a useful tool to enable researchers to more easily test whether particular drugs are effective in attenuating neural effects relating to these conditions.

[@bib75] demonstrated a significant reduction in the number of ventral cochlear nucleus neurons with CB~1~ receptor expression following salicylate administration in rats. However, [@bib76] found that CB~1~ agonists, WIN55,212-2 and CP-55940, were ineffective in eliminating salicylate-induced behavioural deficits, as identified using a conditioned suppression task, and actually induced tinnitus-like behaviour in control rats. In a follow-up study, [@bib74] found that a 1:1 ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administered following noise exposure resulted in a higher number of rats exhibiting tinnitus-like behaviour. However, these cannabinoid agonists are not very selective and may also interact with opioid, vanilloid or muscarinic receptors and this makes the interpretation of their effects more difficult ([@bib48]). These are the only two animal studies to date examining the effects of cannabinoid agonists on tinnitus and further work is required to fully understand these effects ([@bib54]), including the use of more selective agonists.

ACEA is a potent, selective full agonist at the CB~1~ receptor and is highly specific, with a 2000-fold higher affinity for the CB~1~ than the CB~2~ receptor. It is a chemically-modified form of the brain-derived cannabinoid anandamide and may be metabolised in a similar way ([@bib24]). Anandamide is less potent than ACEA and less efficacious (a partial agonist) while another major endocannabinoid in the brain (2-arachidonoyl glycerol) is more efficacious (a full agonist) but less potent. A number of other synthetic cannabinoids were available with high potency and high efficacy, but generally are a lot less selective than ACEA ([@bib48]). The physiological effects of CB~1~ agonists have not been studied in the auditory forebrain but a recent study by [@bib63] demonstrated that CB~1~ receptor knockout mice had deficits in their audiograms above 8 kHz. This suggests a role for CB~1~ receptors in regulating normal hearing, despite their inability to diminish behavioural evidence of tinnitus, and there is a need to further understand the functional significance of the endocannabinoid system in the auditory system ([@bib54]).

We previously demonstrated that salicylate administration significantly reduced wave I ABR amplitudes, increased cortical evoked potentials (EPs) and decreased oscillatory alpha band activity in auditory cortex ([@bib3]). We therefore sought to determine whether these neural changes could be attenuated by ACEA following administration of salicylate in chronically-implanted awake guinea pigs (GPs). We also examined the effects of administering ACEA alone on wave I auditory brainstem amplitudes, cortical evoked potentials and spontaneous oscillatory activity. In a separate group, we assessed whether ACEA could successfully prevent the observation of behavioural evidence of salicylate-induced tinnitus, as assessed using the Preyer reflex gap detection paradigm ([@bib4]). Finally, we examined the effects of ACEA on noise-induced tinnitus-like behaviour in GPs.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

All procedures were carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and the approval of the Animal Welfare and Ethical Review Body at the University of Nottingham, UK. Electrocorticographic (ECoG) recordings were made from a total of 6 male and 3 female tricolour GPs, weighing 500--800 g at the time of implantation (∼2--4 months old). An additional 2 male and 10 female GPs were used for behavioural testing only and were not implanted. Oestrous cycles were not accounted for in female GPs, owing to the fact that, unlike other mammals, they are not easily identified by visual examination in this species when single-sex housed ([@bib56]). Overall gender and age distributions in the current study were similar to our previous study ([@bib3]).

2.2. Electrocorticography (ECoG) array implantation {#sec2.2}
---------------------------------------------------

ECoG arrays were prepared and implanted in the same way as described in [@bib3]. Briefly, 8 uninsulated silver wires with silver ball ends were soldered onto a circuit board attached to a Tucker Davis Technologies (TDT: Alachua, FL, USA) zero insertion force (ZIF)-clip connector. Guinea pigs were initially anaesthetised with ketamine (40 mg/kg, i.p.) and xylazine (8 mg/kg, i.p.), and then artificially respired on an isoflurane/O~2~ mixture during the procedure to maintain a constant state of areflexia. Following a midline incision and clearing of muscle and connective tissue, electrodes were placed through burr holes over the rostral and caudal auditory cortex (AC) on each side, with two more positioned over the cerebellum to record ABRs (see [Fig. 1](#fig1){ref-type="fig"}). Reference and ground electrodes were linked via a jumper on the electrode board and implanted ∼3 mm rostral to bregma, just off the midline on either side. The rostral and caudal electrodes were putatively placed over the dorsorostral edge of primary AC (abbreviated to rostral) and the dorsocaudal area (abbreviated to caudal), respectively ([@bib21]).Fig. 1Diagram showing a connector board in relation to a guinea pig skull. The electrode wires and burr holes are shown diagrammatically with the two most rostral holes for the ground and reference (red and blue) and the holes for the two most caudal holes over the cerebellum (green circles at rear). The cortical burr holes (green lateral circles) and are shown in relation to a diagram of the auditory cortical areas which have been superimposed on the side of the skull. The rostral cortical electrode was placed over the dorsorostral belt at the low frequency edge of the primary auditory cortex (AI). The caudal cortical electrode was placed over the caudal belt at the low-frequency edge of the dorsocaudal core area. Electrodes were positioned in relation to local landmarks on the skull, as the lateral suture that forms the border between the parietal and squamous temporal bones runs obliquely across the middle of AI, just before turning medially to become the coronal suture. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

After electrode insertion, burr holes and the underside of the electrode board were covered with Kwik-Cast silicone sealant (World Precision Instruments: Hitchin, UK) and dental acrylic. The wound was sutured with Mersilk (Ethicon: Livingston, UK) and covered in antibiotic cream. Cyanoacrylate was applied as an adhesive to the wound around the board. GPs were left for at least 24 h following surgery before baseline ECoG recording.

2.3. Recording setup {#sec2.3}
--------------------

The ECoG recording setup has been described in detail elsewhere ([@bib3]). Briefly, chronic ABR and ECoG recordings were performed inside a sound-attenuated chamber, using a ZIF-clip digital headstage attached to the GP\'s implanted electrode. Auditory stimuli were presented free-field via a single ¾-inch tweeter (Tymphany XT19TD00) positioned ∼30 cm above the centre of the cage and were calibrated with two ¼-inch free-field microphones (G.R.A.S. 26AC) placed at either end of the cage prior to each recording session. Recorded ECoG signals were filtered online between 0.5 and 300 Hz for resting state oscillatory activity, 100--5000 Hz for ABRs and 60--300 Hz for EP stimuli. All data were analysed offline with custom-written Matlab (R2014b, MathWorks, MA, USA) scripts. Online data collection was facilitated by either Brainware (software developed by J. Schnupp, University of Oxford, UK) or custom-written Matlab scripts, depending on the types of responses being recorded. Data from electrodes that developed faults were not included in analysis. All experimental conditions (e.g. GP colony, researchers, stimuli, salicylate dose) were the same at those employed in [@bib3].

2.4. ABR stimuli and recording {#sec2.4}
------------------------------

ABRs were recorded from cerebellar electrodes using custom-written Matlab scripts. Pure tones between 5 and 20 kHz (70 dB SPL, 5 ms duration, 0.1 ms on/off ramp) were presented with 500 repeats in a randomised order, and stimulus polarity was alternated to allow cancellation of stimulus artefact. Offline, recordings with an RMS amplitude \>3 absolute deviations above the median were rejected and the remaining data were averaged across repeats. Median absolute deviation was utilised as it has been shown to provide a more robust measure of dispersion than standard deviation when detecting outliers ([@bib33]). Peak-to-trough amplitudes of the largest ABR response (which related to wave I of the subcutaneously-recorded ABR; see [@bib3]) were quantified for each drug treatment and compared to their baseline values. Data from all animals were pooled and treatment effects were assessed statistically with a two-way repeated measures ANOVA and Bonferroni *post-hoc* test. Data were also assessed as changes in ABR amplitude (after treatment values/baseline values) and compared between treatment groups, as well as to the results of [@bib3]. Unpaired *t*-tests were used for determining statistical significance between changes in ABR amplitudes for the different treatment groups (these were assessed as being normally-distributed with the Shapiro-Wilk normality test), and were only applied at the frequency in [@bib3] where we observed a significant deficit (20 kHz), in order to examine each group independently of one another.

2.5. Oscillations and click-evoked responses {#sec2.5}
--------------------------------------------

Resting state oscillatory activity and click-evoked responses were recorded before and after each drug treatment. Data from all baseline sessions were averaged, consisting of 100 repeats for each session. For resting state activity, each repeat constituted 10 s of recording in silence. Data with an RMS \>3 absolute deviations above the median were rejected due to movement artefacts. Power spectral analysis was performed on every 0.5 s sample of this cleaned dataset, resulting in an effective spectral smoothing of 2 Hz, and values were log-transformed in order to express power in decibels (dB) for each frequency. Analysis was completed offline using custom-written Matlab scripts. Statistical analysis comparing baseline resting state activity with that recorded following each drug treatment was performed using a cluster-based permutation test ([@bib37]). This involved performing two-tailed, one sample *t*-tests for each frequency. Frequencies with *t*-values greater than a pre-designated threshold (*p* \< 0.05) were clustered based on spectral adjacency. All *t*-values within each of these clusters were summed to produce a cluster-level statistic and the maximum summed cluster was used as the test statistic. Data were randomised across conditions for each GP and this method was repeated for every possible permutation of the data, creating a distribution of maximum cluster *t*-values. The actual data were then referenced to this distribution, and clusters which fell outside the 95% confidence interval of the distribution were considered significant.

Neural activity was also recorded in response to short clicks (50 μs), with signals attenuated between 0 and 40 dB SPL of full output (∼100 dB SPL), in 10 dB steps, with an interstimulus interval (ISI) of 1500 ms. Comparisons between baseline and drug treatment data were made using peak-to-trough amplitudes measured within 50 ms following the stimulus.

2.6. Drug treatment {#sec2.6}
-------------------

Following baseline data collection, we administered intraperitoneal injections of either (1) sodium salicylate (350 mg/kg) 2 h before repeating the above recordings, with ACEA administered 20 min before these recordings ("salicylate + ACEA", 1 mg/kg, pre-dissolved in anhydrous ethanol at 5 mg/ml; *n* = 5; Tocris, Bristol, UK), or (2) ACEA alone administered 20 min before neural recordings ("ACEA-only", 1 mg/kg; *n* = 4). ACEA was prepared as a mixture with PEG-35 castor oil (Cremophor EL) and saline solution (0.9% NaCl) at a ratio of 1:1:18 and left to mix for at least 10 min in an ultrasonic bath. Salicylate was injected 2 h before neural recordings, as we have previously demonstrated behavioural effects of salicylate treatment after this time ([@bib4], [@bib3]). ACEA was administered 20 min before recordings in both groups, to ensure that we captured the peak effect of the ACEA whilst recordings were ongoing, as ACEA has been shown to act quickly following a systemic injection (within 3 min; [@bib24]) and peak ∼30 min after administration ([@bib24], [@bib49], [@bib52]). Furthermore, at the time we administered ACEA, we would have expected salicylate to already have neural effects ([@bib72]), so we could examine whether such effects were reversed by ACEA. ACEA was administered at a dose of 1 mg/kg; this dosage has been shown to be effective in treating other conditions, such as motor activity following ischemic stroke ([@bib7]), while minimising the *in vivo* tetrad of side-effects caused by CB~1~ agonist administration (e.g. [@bib11]).

2.7. Behavioural testing and noise exposure {#sec2.7}
-------------------------------------------

To determine whether behavioural evidence of tinnitus could successfully be prevented or reversed by administration of ACEA, we performed experiments in two separate groups of non-implanted GPs. These GPs were only used in the behavioural task and no ECoG recordings were performed. The behavioural task employed was the gap detection paradigm originally devised by [@bib65], adapted for use with the pinna reflex in GPs ([@bib4]), whereby a gap in a continuous background signal preceding a startling stimulus can inhibit the subsequent startle response, resulting in a reduced magnitude of the startle reflex compared with when no gap is present. Following interventions that cause tinnitus, the effect of the gap-induced inhibition is impaired. This is often interpreted as evidence of tinnitus, although it should be noted that others have suggested that the test may instead reflect temporal coding deficits (see [@bib19] for a review).

In the first group (*n* = 3), we recorded gap detection behavioural responses to broadband noise (BBN) stimuli across six trials per GP, before and 2 h following sodium salicylate administration (350 mg/kg; i.p.). BBN stimuli were selected as we have previously seen reliable gap detection deficits with this background carrier following the same dose of salicylate and at the same time point ([@bib4], [@bib3]). Furthermore, focussing on one background frequency meant that our data yield and statistical power was much greater than previously, resulting in *n* = 18 gap-induced prepulse inhibition (gap-PPI) trials from 3 GPs at each time point. Sound levels of the background carrier (55, 60, or 70 dB SPL) and startling stimuli (95, 100, or 105 dB SPL) were determined prior to baseline recording with a sound level-dependency test (SLDT; see [@bib3]). Briefly, this involved presenting all different sound level combinations and assessing which combination produced the best level of gap-PPI for each GP, along with a reliable startle response -- the optimal levels were then used in baseline and post-treatment trials. Gap duration (50 ms) and number of gap/no gap presentations (10 of each per trial) were identical to regular trials, and each trial lasted ∼2 min. This procedure was performed on a separate day prior to baseline data collection.

ACEA was co-administered 20 min before post-salicylate behavioural testing at the same dose as that used in the ECoG GPs (1 mg/kg; i.p.), with the hypothesis that if ACEA was successful in attenuating neural changes underlying tinnitus, there would be no significant difference between gap/no gap startle ratios before vs after salicylate + ACEA treatment -- that is, a gap detection deficit consistent with the presence of tinnitus would not be evident. Behavioural gap detection data across GPs were grouped and statistical significance was assessed using a Wilcoxon matched-pairs signed rank test with an alpha of *p* \< 0.05.

In the second group (*n* = 9), we assessed whether ACEA could successfully reverse behavioural evidence of noise-induced tinnitus. Baseline behavioural data were collected for five different background carrier frequencies (BBN, 4--6 kHz, 8--10 kHz, 12--14 kHz, 16--18 kHz), as we have previously found gap detection deficits at a variety of frequencies following the same noise exposure, unlike the uniformity of deficits with salicylate ([@bib10]). Behavioural sound levels (background: 55, 60 or 70 dB SPL; startling stimulus: 95, 100 or 105 dB SPL) were selected with an SLDT (see above). Each trial consisted of 10 startling stimuli with a gap preceding and 10 startling stimuli with no gap preceding.

Noise exposure was performed in a similar manner as described in [@bib10] and [@bib5]. Briefly, GPs were anaesthetised with ketamine (50 mg/kg, i.p.; Fort Dodge Animal Health Ltd, Southampton, UK) and xylazine (10 mg/kg, i.p.; Bayer PLC, Newbury, UK), supplemented with further administrations of a mixture of ketamine and xylazine, in a ratio of 15:2 (i.m.), throughout the procedure. Core body temperature was monitored throughout and maintained at 38 ± 0.5 °C using a homeothermic heating pad (Harvard Apparatus Ltd, Edenbridge, UK) and a rectal probe. Polyethylene tubes (diameter 20 mm) were connected to 25-mm loudspeakers (Peerless DX25). The right one was disconnected and plugged with cotton wool, and placed over the folded right ear, in order to prevent auditory deficits in the right ear. The left speaker was calibrated using a 40BP 0.25-inch pressure condenser microphone, 26AC preamplifier and 12AR power supply (all G.R.A.S, Holte, Denmark) attached to a calibrated 1-mm-diameter probe positioned near the entrance to the ear canal. GPs were placed inside a sound-proof booth and remained there for the duration of the acoustic trauma. The left ear was exposed to narrow band-passed noise bursts (duration of 500 ms and ISI of 200 ms; centre frequency 10 kHz; bandwidth 1 kHz), presented at 116 dB SPL, for 1 h.

Behavioural testing was performed between 7 and 8 weeks following noise exposure in order to determine whether tinnitus was present. Each GP was assessed for tinnitus-like behaviour individually, by comparing sessions recorded after noise exposure with sessions recorded before noise exposure. Tinnitus frequencies were identified using a two-way ANOVA with Bonferroni post-hoc correction (data were normally distributed, as assessed with the Shapiro-Wilk normality test). Average behavioural gap/no gap ratios, at frequencies where a significant deficit was present, were compared to baseline values at the same frequencies, in order to determine the degree of change in behavioural response at the purported tinnitus frequency/frequencies (calculated by dividing the mean of baseline gap/no gap ratios by the mean of post-noise exposure ratios).

GPs were then tested on a further five separate occasions 20 min after administering ACEA (1 mg/kg; i.p). Two GPs with gap detection deficits were reserved for administering ACEA vehicle-only 20 min before behavioural recording. ACEA vehicle was prepared and administered using the same ratio as described earlier for ACEA, but with ethanol substituted for ACEA. The worst session from each time point (baseline, 7--8 weeks and 'treatment') was discarded prior to analysis to prevent skewing of the data, for example, on days when GPs were particularly active. Average gap/no gap ratios for the tinnitus frequency/frequencies following treatment were compared to baseline values and Wilcoxon signed rank tests were used to compare changes in gap/no gap ratios across GPs after treatment vs 7--8 weeks, in order to determine whether ACEA or vehicle administration could significantly affect behavioural evidence of noise-induced tinnitus.

3. Results {#sec3}
==========

3.1. ABR wave I amplitudes {#sec3.1}
--------------------------

Suprathreshold (70 dB SPL) ABRs were recorded before and 2 h after salicylate administration, as well as 20 min after ACEA administration, for five different frequencies: 5 kHz, 7.07 kHz, 10 kHz, 14.1 kHz and 20 kHz. Previously, we observed a significant decrease in ABR amplitudes following salicylate administration (without co-administration of ACEA; [@bib3]). Average ABR wave I amplitudes for both treatments are shown in [Fig. 2](#fig2){ref-type="fig"}. Contrasting with the results of [@bib3], when ACEA was co-administered with salicylate (salicylate + ACEA group), there was no significant effect of treatment on ABR amplitudes for either the left ear (F~(1,10)~ = 2.83, *p* = 0.12) or the right ear (F~(1,15)~ = 3.88, *p* = 0.07), although a small reduction in wave I amplitudes was evident at 20 kHz for both ears ([Fig. 2](#fig2){ref-type="fig"}A and B), albeit not to a statistically significant extent. Furthermore, there was no significant effect of treatment on ABR amplitudes for the left ear (F~(1,10)~ = 3.04, *p* = 0.11) or the right ear (F~(1,15)~ = 0.02, *p* = 0.90) following administration of ACEA by itself (ACEA-only group), thereby suggesting that ACEA did not simply increase ABR wave I amplitudes ([Fig. 2](#fig2){ref-type="fig"}C and D).Fig. 2Mean peak-to-trough amplitudes of ABRs, recorded from cerebellar electrodes, for each of the five frequencies recorded. Data are shown for baseline and salicylate + ACEA for left (**A**; *n* = 3) and right (**B**; *n* = 4) ears, as well as baseline and ACEA-only for left (**C**; *n* = 3) and right (**D**; *n* = 4) ears. Change in amplitudes are shown for left (**E**) and right (**F**) ears as after treatment/before treatment ratios, whereby a ratio of 1 indicates no difference in ABR amplitude (dotted line) and a lower ratio highlights a greater reduction in amplitude after treatment. Maroon bars are data from [@bib3], wherein salicylate was administered without ACEA. Co-administration of ACEA attenuated the salicylate-induced reductions observed previously. Error bars indicate SEM. \**p* \< 0.05; \*\**p* \< 0.01. **G and H:** Grand averaged ABR waveforms, using data from [@bib3]; **G**) compared to salicylate + ACEA (**H**). These consist of the means across GPs (averaged across repeats) in response to 20 kHz. ACEA attenuated the wave I reductions caused by salicylate, and increases in latencies were not as clear. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

Changes in ABR amplitudes at 20 kHz were also compared directly with the results of [@bib3]; [Fig. 2](#fig2){ref-type="fig"}E and F) and expressed as a ratio calculated as after treatment amplitude/before treatment amplitude, whereby a ratio of 1 indicated no difference in ABR amplitude and lower ratios highlighted a greater reduction in amplitude, as we previously observed a significant deficit at this frequency following salicylate administration alone. For the left ear, in the salicylate + ACEA group, there were some reductions evident in ABR amplitudes, giving a mean ratio (±SEM) of 0.55 (±0.03), but this change was significantly smaller than what we found previously when administering salicylate alone ([@bib3]; maroon bars), *t* (6) = 4.96, *p* = 0.003, wherein the mean ratio (±SEM) was 0.27 (±0.04). For the right ear, this change was again significantly smaller in the salicylate + ACEA group compared to the previous data from [@bib3], *t* (7) = 2.63, *p* = 0.03, with a mean ratio (±SEM) of 0.54 (±0.13) compared with a mean ratio of 0.20 (±0.05) when salicylate was administered without ACEA. This attenuation of the salicylate-induced reductions of wave I amplitudes by ACEA is further emphasised by [Fig. 2](#fig2){ref-type="fig"}G and H, which show left ear grand averages of ABRs in salicylate GPs (from [@bib3]) compared to salicylate + ACEA.

ACEA administered alone resulted in a mean change in ABR ratios at 20 kHz on the left and right of 1.20 (±0.34) and 1.24 (±0.14) respectively. For the left ear, these were significantly higher than the [@bib3] ratios, *t* (6) = 3.70, *p* = 0.01, but not significantly different than the salicylate + ACEA ratios, *t* (4) = 1.93, *p* = 0.13. For the right ear, these ratios were significantly higher than both the [@bib3] ratios, *t* (7) = 7.65, *p* = 0.0001, and the salicylate + ACEA ratios, *t* (6) = 3.59, *p* = 0.01. These data further highlight that, although salicylate was still affecting ABR sensitivity, co-administration of ACEA appeared to attenuate the effects of salicylate on ABR amplitudes at the highest frequency we assessed (20 kHz).

3.2. ABR wave I latencies {#sec3.2}
-------------------------

Latencies of the N1 and P1 components of wave I of the ABR were compared for salicylate + ACEA and ACEA alone at all five frequency bands, as we had previously demonstrated a significant increase in P1 and N1 latencies at 20 kHz following salicylate administration ([@bib3]), with increases between 0.12 and 0.16 ms. In the salicylate + ACEA group, there was a general effect of treatment across GPs, with an increase in P1 latencies for the left ear (0.04 ms ± 0.01 SEM; F~(1,10)~ = 4.97, *p* = 0.05) and the right ear (0.06 ms ± 0.01 SEM; F~(1,15)~ = 16.93, *p* = 0.0009), although *post-hoc* testing revealed that there was not one particular frequency with a significant increase in P1 latency. There was also a general increase in N1 latencies across GPs for the left ear (0.04 ms ± 0.01 SEM; F~(1,10)~ = 8.65, *p* = 0.01) and the right ear (0.07 ms ± 0.02 SEM; F~(1,15)~ = 24.66, *p* = 0.0002), although the only particular frequency with a significant increase was 20 kHz for the right ear (t = 3.490, *p* \< 0.05), with a mean increase of 0.11 ms (±0.03 ms). In the ACEA-only group, there was no significant effect of treatment on N1 latencies for the left ear (F~(1,10)~ = 2.61, *p* = 0.14) or the right ear (F~(1,15)~ = 2.16, *p* = 0.16), and the same was true for P1 latencies in both the left ear (F~(1,10)~ = 0.02, *p* = 0.89) and the right ear (F~(1,15)~ = 0.01, *p* = 0.92).

3.3. Click-evoked cortical EPs {#sec3.3}
------------------------------

[Fig. 3](#fig3){ref-type="fig"} shows EPs in response to 50 μs clicks before vs after the administration of either salicylate + ACEA or ACEA alone, averaged across GPs and recorded with a signal attenuation of 0 dB SPL (approximately 100 dB SPL RMS), while [Fig. 4](#fig4){ref-type="fig"} shows peak-to-trough responses for both groups across all sound levels. Salicylate + ACEA resulted in increases in click-EPs, similar to what we have observed previously with salicylate only ([@bib3]), ranging from 61 to 89% for rostral AC and 145--159% for caudal AC ([Fig. 4](#fig4){ref-type="fig"}A and B). All of these increases were significant (*p* \< 0.05), with the greatest effects seen at the loudest sound levels. There were no clear or significant changes in cerebellar click-evoked potentials ([Fig. 4](#fig4){ref-type="fig"}C). ACEA alone slightly increased EPs for all electrodes ([Fig. 4](#fig4){ref-type="fig"}D--F), although there was a considerable degree of variability across GPs and the effect was much lower than that caused by salicylate + ACEA, ranging from 34 to 48% for rostral AC, 30--39% for caudal AC and 24--54% for cerebellar electrodes. Nonetheless, these changes were significant for rostral AC and caudal AC at the loudest sound levels (between 20 and 0 dB attenuation; *p* \< 0.05), but were not significant for cerebellar EPs at any sound level. In summary, these data indicate that co-administration of ACEA did not attenuate the increases in click-EPs caused by salicylate, and ACEA alone caused slight increases in EPs.Fig. 3Click-evoked potentials. **A** and **B:** Mean responses across GPs (±SEM; *n* = 5) from rostral AC and caudal AC, recorded during baseline (blue) and after salicylate + ACEA treatment (green). Shading indicates SEM. **C** and **D:** Mean responses across GPs (±SEM; *n* = 4) from rostral AC and caudal AC, recorded during baseline (blue) and after treatment with ACEA alone (black). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3Fig. 4Mean peak-to-trough amplitudes of click-evoked responses across GPs (±SEM) for all attenuations recorded during baseline and after drug administration from rostral AC (**A** and **D**), caudal AC (**B** and **E**) and ABRs (**C** and **F**). \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.0001.Fig. 4

3.4. Cortical oscillatory activity {#sec3.4}
----------------------------------

Data recorded in silence from rostral and caudal electrodes were fast Fourier transformed in order to produce power spectra. [Fig. 5](#fig5){ref-type="fig"} shows mean power spectra averaged across GPs for each group, collected before and after each treatment. Cluster-based permutation analyses were applied to determine statistical significance with an alpha level of *p* \< 0.05. In the salicylate + ACEA group, there was a significant decrease in activity between 22 and 34 Hz on the rostral electrodes ([Fig. 5](#fig5){ref-type="fig"}A). However, co-administration of ACEA with salicylate did not produce any significant changes in oscillatory activity on the caudal electrodes ([Fig. 5](#fig5){ref-type="fig"}B). ACEA administered alone did not cause any significant changes on either the rostral electrodes ([Fig. 5](#fig5){ref-type="fig"}C) or the caudal electrodes ([Fig. 5](#fig5){ref-type="fig"}D). In summary, the change in oscillatory alpha band activity that we have observed previously following salicylate treatment ([@bib3]) was not present when ACEA was co-administered.Fig. 5Mean resting-state activity power spectra (±SEM), recorded during baseline and following either salicylate + ACEA (**A**, caudal and **B**, rostral; *n* = 5) or ACEA-only (**C**, caudal and **D**, rostral; *n* = 4). Blue lines indicate baseline activity and blue or black lines indicate activity following drug treatment. Magenta shading between lines in (**A**) highlights significant difference. Inset figures (furthest right) show expanded area where a significant difference was demonstrated previously following salicylate treatment ([@bib3]). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 5

3.5. Behavioural responses following salicylate + ACEA administration {#sec3.5}
---------------------------------------------------------------------

[Fig. 6](#fig6){ref-type="fig"} shows behavioural responses before and after salicylate + ACEA co-administration, plotted as ratios of gap/no gap, which are indicative of the degree of gap-PPI. Following salicylate + ACEA administration, there was a significant increase in the gap-PPI ratio across GPs (*p* = 0.026), similar to what we have seen previously when administering salicylate alone ([@bib4], [@bib3]). This indicates that behavioural gap detection ability was impaired following co-administration of both drugs, which is suggestive of the presence of tinnitus and demonstrates that ACEA failed to prevent behavioural identification of salicylate-induced tinnitus. Furthermore, these data were compared directly with data from [@bib3], wherein salicylate was administered without ACEA. When examining the change in gap-PPI as a function of before salicylate vs after salicylate, calculated for each GP by dividing gap-PPI ratios before drug administration by gap-PPI ratios after, the mean change in gap-PPI ratio (before/after) following salicylate + ACEA was 0.80 (±0.34 SEM), compared to 0.77 (±0.07 SEM) following salicylate without ACEA (data from [@bib3]). This difference was not significant (*U* = 6, *p* = 0.79), further highlighting that ACEA did not attenuate the behavioural effects of salicylate.Fig. 6**A**: BBN Behavioural gap detection ratios (gap-PPI) before and after salicylate + ACEA administration, averaged across GPs (*n* = 3 GPs, 18 gap-PPI trials). There was a significant increase in the gap detection ratio of the pinna reflex following co-administration of the two drugs, which highlights that gaps in otherwise continuous background noise were less effective at inhibiting the response following a startling stimulus, consistent with the presence of tinnitus (\**p* \< 0.05). **B:** Mean change from baseline in gap-PPI across GPs (±SEM) following salicylate + ACEA, compared with data from [@bib3] wherein salicylate was administered without ACEA. A value of 1 would indicate no change in behavioural gap detection ability compared to baseline, whilst higher values would suggest improvement and lower values worsening. There was no significant difference between the two groups.Fig. 6

3.6. Behavioural responses in noise exposed GPs {#sec3.6}
-----------------------------------------------

Behavioural testing for evidence of tinnitus 7--8 weeks following unilateral noise exposure indicated that 7 of the 9 GPs demonstrated significant gap detection deficits at one of more of the frequencies tested, which is proportionally comparable to what we have observed previously with a similar noise exposure ([@bib10]). In some cases, behavioural gap detection deficits were observed at more than one background frequency. There were significant deficits at 4--6 kHz in four GPs, 12--14 kHz in two GPs, 16--18 kHz in two GPs and BBN in one GP. [Fig. 7](#fig7){ref-type="fig"}A shows an example of a GP with a significant deficit at 4--6 kHz, expressed as a change in gap-PPI after noise exposure vs before.Fig. 7Change in behavioural gap detection ratios (gap-PPI) 7--8 weeks following noise exposure and ACEA administration. **A:** An example of a GP with behavioural evidence of tinnitus. Gap detection ability was significantly worse at the 4--6 kHz background carrier seven-to-eight weeks following noise exposure, compared to baseline (grey bar; \**p* \< 0.05). **B:** Change in gap-PPI at the tinnitus frequency for each time point, compared to baseline (*n* = 6 frequencies for ACEA; *n* = 3 frequencies for vehicle), averaged across GPs. There were no significant changes in behavioural gap detection deficits following either ACEA administration (green bars) or vehicle treatment (maroon bars). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 7

Following behavioural testing for tinnitus, GPs were administered either ACEA or ACEA-vehicle on five separate occasions and their behavioural responses were recorded. Behavioural responses at the suggested tinnitus frequency/frequencies were expressed as an average change in gap-PPI at either the 7--8 week time point or the treatment time point compared to baseline, and data were grouped across GPs. The data for these GPs are shown in [Fig. 7](#fig7){ref-type="fig"}B. There was no significant difference in the change in gap-PPI at purported tinnitus frequencies between the 7--8 week time point and the treatment time point, for either ACEA administration (*p* = 0.16; *n* = 6 frequency bands from 5 GPs) or vehicle administration (*p* = 0.25; *n* = 3 frequency bands from 2 GPs), thereby highlighting that ACEA did not significantly affect behavioural evidence of noise-induced tinnitus.

4. Discussion {#sec4}
=============

The synthetic cannabinoid agonist, ACEA, attenuated some of the effects that we previously observed with salicylate administration. Namely, it attenuated the reductions in ABR wave I amplitudes and the increases in peak latencies, as well as abolishing decreases in cortical oscillatory activity within the 6--10 Hz band. However, increases in cortical evoked potentials caused by salicylate were not attenuated by co-administration of ACEA. Furthermore, behavioural evidence of both salicylate- and noise-induced tinnitus was still evident following administration of ACEA, suggesting that highly-selective CB~1~ agonists do not prevent the identification of tinnitus or reverse the presence of tinnitus.

4.1. Potential otoprotective effects of ACEA {#sec4.1}
--------------------------------------------

We previously demonstrated that wave I amplitudes were significantly reduced following salicylate administration at 20 kHz ([@bib3]). Following co-administration of ACEA with salicylate, although there were still reductions in wave I amplitudes, these effects were diminished and not significant, suggesting that ACEA had attenuated the ototoxic effects of sodium salicylate. Changes in latencies following salicylate were also attenuated by co-administration of ACEA. Moreover, ACEA administered alone did not cause changes in wave I ABR amplitudes.

Salicylate is known to cause reversible ototoxicity ([@bib61]), which may occur through a reduction in outer hair cell electromobility (e.g. [@bib28]). This would result in a reduction in cochlea sensitivity, which could explain the decreases in wave I ABR amplitudes that we have previously observed. Given that the attenuating effect of ACEA that we have observed here is purely phenomenological, we can only speculate as to the underlying mechanisms. There is recent evidence that CB~1~ receptors are present in the cochlea, although the CB~2~ receptors appeared more prevalent ([@bib38]). Furthermore in the same study, following cisplatin treatment, which produces ototoxicity, CB~1~ receptor expression was downregulated in spiral ganglion neurons. [@bib27] also demonstrated that a CB~1~ agonist, HU-210, could prevent apoptosis of hair cells following cisplatin treatment. Recent data suggest that salicylate may kill spiral ganglion neurons over the course of several days as a result of enhancing activation of NMDA receptors ([@bib13]).

Cannabinoids have been shown to prevent neurotoxicity caused by over-activation of NMDARs in other conditions (e.g. [@bib16]), as they can act in a similar manner to non-competitive NMDAR antagonists ([@bib17]). Therefore, by activating CB~1~ receptors it is possible that we attenuated processes that would lead to the apoptotic effects of salicylate that have previously been demonstrated ([@bib66], [@bib18]). All of the above, combined with the fact that mice missing CB~1~ receptors possess poorer hearing thresholds than wild-type mice ([@bib63]), suggests an important role for CB~1~ receptors in protecting and maintaining normal hearing function. Clearly further work is required in order to determine the specific underlying mechanisms by which activation of CB~1~ receptors may attenuate damage caused by salicylate.

Furthermore, it would be of interest to determine whether ACEA is successful at attenuating damage to the periphery caused by noise exposure. Given that we did not examine ABRs in our noise exposed GPs following ACEA administration, we are unable to determine whether this was the case in our GPs. Recent work by [@bib74] did not find a difference in ABR thresholds between noise-exposed rats administered delta-9-THC and CBD, so the effects seen here may only be apparent in salicylate-induced hearing loss. However, absolute ABR thresholds do not appear to be as sensitive as ABR amplitudes at suprathreshold sound levels in measuring the extent of damage at the periphery ([@bib31]). It is also possible that administering a CB~1~ agonist prior to an acoustic insult (as opposed to after) may prevent subsequent damage, rather than reversing already-induced damage. If this was the case, however, then the impact of such a treatment would be limited in humans, as it would not reverse pre-existing damage.

4.2. No effect on cortical evoked potentials {#sec4.2}
--------------------------------------------

Despite the attenuation of effects observed at the periphery, co-administration of ACEA failed to attenuate the effects of salicylate on cortical evoked potentials, and in fact significantly increased click-evoked potentials at the highest sound levels when administered alone. To our knowledge, this is the first demonstration of effects of a CB~1~ agonist on auditory cortex EP amplitudes, although enhancements in EPs have previously been demonstrated in the hippocampus with the CB~1~ agonist WIN55,212-2 ([@bib14]). This also suggests a central mechanism for salicylate-induced hyperacusis, independent of peripheral activity, an idea supported by others ([@bib59], [@bib9], [@bib51]). There is clear evidence that salicylate administered systemically enters both the cochlear perilymph and cerebrospinal fluid ([@bib25]), thereby directly affecting auditory areas of the central nervous system (see [@bib58] for a review). Therefore, it is not inconsistent that we observed different effects on wave I ABR activity to cortical evoked activity, as both drugs would likely act peripherally and centrally.

CB~1~ receptors are present in cholecystokinin-expressing large basket cells in the neocortex (e.g. [@bib6]), which are inhibitory interneurons. In these neurons, CB~1~ receptors are located presynaptically, which has a net effect of depressing inhibition (see [@bib1] for a review). This is evidenced by the fact that administration of a CB~1~ agonist suppresses inhibition in layers 2/3 of the auditory cortex ([@bib64]). Therefore, it is perhaps not surprising that EP amplitudes were slightly enhanced by cannabinoids. Consistent with this finding, [@bib22] reported hyperacusis in humans as an adverse side effect of oral administration of CBD:THC prepared as a 1:1 ratio.

4.3. Decreases in alpha band oscillations absent following co-administration of salicylate with ACEA {#sec4.3}
----------------------------------------------------------------------------------------------------

We previously demonstrated a significant reduction in alpha band activity in caudal AC following salicylate administration ([@bib3]). Following co-administration of ACEA, significant changes in alpha band activity were not present in the current study. If a reduction in alpha band activity is a neural correlate of tinnitus, then this would suggest that ACEA was successfully eliminating the neural underpinnings of tinnitus. However, [@bib76], [@bib74] found that CB~1~ agonists were ineffective at reducing behavioural evidence of tinnitus following either salicylate or noise exposure. Furthermore, we found that ACEA was unsuccessful in preventing behavioural evidence of salicylate-induced tinnitus or reversing behavioural evidence of noise-induced tinnitus, which is consistent with the results of [@bib76], [@bib74]. Therefore, even if a reduction in alpha band activity is an underlying contributor to the tinnitus percept, given that a cannabinoid agonist did not abolish behavioural evidence of tinnitus, but did prevent changes in alpha band activity following salicylate administration, it appears unlikely that it is necessary for generating the phantom percept.

One limitation of the current study is that the effect of vehicle administration on behavioural deficits following noise exposure was only examined in two guinea pigs (one of which had putative tinnitus at two background frequencies, resulting in *n* = 3 tinnitus frequencies before vs after vehicle). Therefore, although we did not observe any effect, the statistical test in this case would have likely been underpowered. However, behavioural deficits following noise exposure were also unchanged following ACEA administration (with *n* = 6 putative tinnitus frequencies), which made the comparison with vehicle GPs less crucial. As a result, we do not feel that the low number of vehicle controls significantly affects the conclusions we can draw from the data.

Significant decreases in low gamma activity were evident in rostral AC following co-administration of salicylate and ACEA. We demonstrated previously that both a vehicle and a salicylate injection were capable of producing increases in gamma activity in this same region ([@bib3]), which we suggested may be a result of stress associated with the injection. The decreases in gamma we have observed here therefore suggest that the ACEA injection may actually reduce stress in these GPs. This idea, however, is not supported by the fact that we did not see any significant changes following an injection of ACEA alone. Therefore, there could be an interaction effect between salicylate and ACEA that results in this change in low gamma activity.

Whilst we did not observe such a reduction in gamma band activity with administration of ACEA only, previous studies have demonstrated that another CB~1~ agonist, CP-55940, reduced gamma oscillations in other areas, including in the hippocampus and entorhinal cortex ([@bib53], [@bib23]) and prefrontal cortex ([@bib29]). Conversely, [@bib43] failed to find a difference in neural oscillations in the medial entorhinal cortex following application of the CB~1~ agonist arachidonylcyclopropylamide (ACPA) *in vitro*. Nonetheless, clearly further research is required to properly understand the mechanisms underlying changes in oscillatory activity observed here.

In summary, ACEA appeared to attenuate salicylate-induced reductions in wave I of the ABR and alpha-band neural oscillations, but did not attenuate salicylate-induced increases in cortical evoked potentials or affect tinnitus-like behaviour. This suggests that ACEA may be potentially otoprotective, and that hyperacusis-like activity may occur independent of peripheral insult, but CB~1~ agonists are not suitable as a potential treatment for tinnitus. Further research is necessary to determine whether ACEA can effectively attenuate peripheral damage caused by excessive noise exposure.
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